Key Details
Price
$64.95Last Dividend
$0.18Annual Revenue
$1.25 BAnnual EPS
$2.59Annual ROE
3.75%Beta
0.74Events Calendar
Next earnings date:
Jan 24, 2025Recent quarterly earnings:
Oct 25, 2024Recent annual earnings:
Jan 26, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Nov 08, 2024Next split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
It's a new year, and with that, the 2025 S&P 500 forecasts from the big names on Wall Street are in.
Brian Nagel, Oppenheimer senior analyst, joins 'Closing Bell: Overtime' to discuss Nike earnings and his outlook for the stock.
Strategic Recruitments of Persio 'Tony' Perez, Michael Chatman and Bill Dolan as Managing Directors Builds on Growth Momentum of Fixed Income Team Senior-Level Hires Enhance Oppenheimer's Capabilities in Emerging Markets Sales, Trading and Research Solutions NEW YORK , Dec. 17, 2024 /PRNewswire/ -- Oppenheimer & Co. Inc. (Oppenheimer) — a leading investment bank, wealth manager and a subsidiary of Oppenheimer Holdings (NYSE: OPY) — announced today the continued expansion of its Fixed Income Division with the addition of three new Managing Directors to the Emerging Markets Desk in New York. Joining the firm are Persio "Tony" Perez, EM Sales Manager; Michael Chatman, EM Sales; and Bill Dolan, EM Sovereign Trading.
Brian Nagel, Oppenheimer senior equity research analyst, joins 'Closing Bell Overtime' to talk Lululemon quarterly results.
PHOENIX, Dec. 04, 2024 (GLOBE NEWSWIRE) -- WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary flexible space solutions, today announced that it will participate in the Oppenheimer Midwest Virtual Summit on December 11, 2024.
—Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companies with “Key, Near-Term, Potentially Stock-Moving Catalysts”— TEL AVIV, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it will participate in Oppenheimer's Movers in Rare Disease Summit on Thursday, December 12, 2024, at the Westin Grand Central in New York City.
Brian Nagel, Oppenheimer senior analyst, joins 'Squawk Box' to break down Home Depot's Q3 earnings results.
The Investment Committee debate the big bank names.
Oppenheimer's earnings report show strength in mid-market capital markets franchise as well as solid growth in the rest of its AUM and commission based businesses. Risk taking in public markets has driven the bulk of the company's performance, and capital markets did well despite the lack of major PE activity. OPY looks attractive in terms of valuation, with forward multiples below 10x, making it cheaper compared to peers like Lazard, which trades at around 20x.
NEW YORK , Oct. 25, 2024 /PRNewswire/ - Oppenheimer Holdings Inc. (NYSE: OPY) (the "Company" or "Firm") today reported net income of $24.5 million or $2.38 basic earnings per share for the third quarter of 2024, compared with net income of $13.9 million or $1.32 basic earnings per share for the third quarter of 2023. Revenue for the third quarter of 2024 was $373.4 million, an increase of 19.4%, compared to revenue of $312.7 million for the third quarter of 2023.
FAQ
- What is the primary business of Oppenheimer Holdings?
- What is the ticker symbol for Oppenheimer Holdings?
- Does Oppenheimer Holdings pay dividends?
- What sector is Oppenheimer Holdings in?
- What industry is Oppenheimer Holdings in?
- What country is Oppenheimer Holdings based in?
- When did Oppenheimer Holdings go public?
- Is Oppenheimer Holdings in the S&P 500?
- Is Oppenheimer Holdings in the NASDAQ 100?
- Is Oppenheimer Holdings in the Dow Jones?
- When was Oppenheimer Holdings's last earnings report?
- When does Oppenheimer Holdings report earnings?